MedTrace Logo

A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects

NCT07293390 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-12-19

No results posted yet for this study

Summary

To analyze radioactivity excretion and pharmacokinetics in healthy subjects after a single oral dose of \[¹⁴C\]TQ05105, identifying excretion routes, major metabolites, and biotransformation pathways. Secondary: To determine pharmacokinetics of TQ05105 and metabolites (e.g., TQ12550) via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and assess treatment safety.

Conditions

  • Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects

Interventions

DRUG

TQ05105

Janus Kinase 2 (JAK2) inhibitor

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-18
Primary Completion
2024-04-08
Completion
2024-08-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07293390 on ClinicalTrials.gov